Insulet's Identity Crisis: Elite Business, Broken Stock, and a CEO Putting Her Own Money Where Her Mouth Is

Here's the trade that should make every value investor's pulse quicken and every momentum trader run for the exits: a company growing sales at nearly 30% a year, throwing off 72% gross margins, and posting a 26% return on equity — down 57% over the past twelve months. That's PODD right now. Somewhere between "best-in-class medical device franchise" and "chart that looks like it fell down a flight of stairs," Insulet has become one of the more fascinating standoffs in healthcare tech.

Let's start with what actually happened. On August 5, Insulet reported Q2 2026 revenue of $801.7 million, up 23.5% year-over-year — a genuine beat. That followed an even hotter Q1, where revenue jumped 33.9% and net income nearly tripled to $91.1 million. This is not a company running out of gas on the top line. International Omnipod sales are guided to grow 28-30% for the year, and the "global leader in tubeless insulin pump technology" tag isn't just marketing copy — it's a real competitive moat against Medtronic and Tandem.

So why did the stock get hammered on a beat? Because guidance for next quarter — $833.4 million — landed 1.6% below what analysts wanted, and because growth decelerated from Q1's blistering 33.9% down to Q2's still-strong-but-notably-slower 23.5%. In a market that's been trained to punish deceleration in growth names regardless of the absolute number, that was enough. Layer on top of that a real, self-inflicted problem: weaker-than-expected retention among Type 2 diabetes patients on the Omnipod platform, an issue serious enough that CEO Ashley McEvoy has publicly admitted the company "should have identified the issue sooner." That's the kind of admission that makes analysts nervous and multiples compress. Sure enough, the average price target has slid from $225 to $203, with TD Cowen slashing its target from $294 all the way down to $144 and Leerink joining the downgrade parade. There's also a securities litigation notice floating around from July tied to pre-February 2025 shareholders — an overhang worth watching, even if the merits remain foggy.

Put it together and you get a stock that's now trading -34% below its 200-day moving average, sitting just above its 52-week low of $126.40, in a clean, ugly downtrend from north of $350. The tape is broken. Full stop. RSI in the low 40s isn't even oversold yet — this thing can keep bleeding.

But here's where it gets interesting. At current levels, PODD trades at 18.5x forward earnings and a PEG ratio of just 0.80. For a company still growing sales at a 29% TTM clip with margins most device makers would kill for, that's a valuation that hasn't been this cheap in years. And somebody with the best information in the building apparently agrees: McEvoy bought $162,000 of stock in the open market on August 24 at $147.47 — not a huge check relative to her overall comp, but the first real insider buy signal at these depressed levels, and directionally meaningful when a CEO is putting personal capital behind a company she just publicly copped to mismanaging on the operational side.

My take: this is not a "back up the truck" moment, and anyone telling you it is hasn't looked at the chart. The technical structure is genuinely broken, the Type 2 retention issue is unresolved, and the guidance cadence has lost credibility with the sell-side — that's not nothing. But the fundamental engine — margins, ROE, international runway, category leadership — hasn't gone anywhere. This looks like a case where the stock has overshot the operational problem to the downside, and valuation plus insider buying are starting to offer real compensation for the risk.

The playbook here is patience, not heroics: scale in on weakness in the $138-142 zone, keep a hard stop below that $126.40 low, and don't get seduced into chasing strength until price reclaims $155 on real volume. Q3 earnings in early November will be the tell — either management shows it's fixed the Type 2 onboarding leak and reasserts guidance credibility, or this turns into a longer value trap. Until then, PODD is a stock you accumulate carefully, not one you fall in love with.